165 - Era of Resistance: The Most Difficult Gram-Negative Cases

Friday, October 18, 2024

1:45 PM – 3:00 PM US PT

Location: Concourse 151

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Interactive Moderator(s)

Sara Karaba, MD, PhD, MHS

Assistant Professor
Johns Hopkins University
Baltimore, MD, United States
Jeffrey Gerber, MD, PhD (he/him/his)

Professor of Pediatrics and Epidemiology
Pediatrics
Children's Hospital of Philadelphia
Philadelphia, PA, United States

Slides

Moderator(s)

Yohei Doi, MD, PHD (he/him/his)

Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh
Toyoake, Aichi, Japan

Panelist(s)

Fatma Ben Abid, MD

Consultant
Division of Infectious Diseases
Hamad Medical Corporation
Doha, Ad Dawhah, Qatar
Frank Tverdek, PharmD

Antimicrobial Stewardship Pharmacist
Fred Hutchinson Cancer Center / University of Washington
bellevue, WA, United States
Robert Bonomo, MD (he/him/his)

Associate Chief of Staff for Academic Affairs
Division of Medicine
Case Western Reserve University/ Louis Stokes Cleveland VA Medical Center
Cleveland, OH, United States
Ghady Haidar, MD (he/him/his)

Associate Professor of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA, United States

Disclosure(s):

Sara M. Karaba, MD, PhD, MHS: Entasis: Advisor/Consultant

Jeffrey S. Gerber, MD, PhD: No financial relationships to disclose

Yohei Doi, MD, PHD: AbbVie: Advisor/Consultant (Terminated, October 31, 2023); bioMerieux: Advisor/Consultant (Terminated, December 31, 2022); Entasis Pharmaceuticals: Grant/Research Support (Ongoing); FujiFilm: Advisor/Consultant (Terminated, December 31, 2022); Gilead: Advisor/Consultant (Terminated, November 30, 2023), Honoraria (Terminated, November 30, 2023); GlaxoSmithKline (GSK): Advisor/Consultant (Terminated, March 31, 2023); Meiji Seika Pharma: Advisor/Consultant (Ongoing); Moderna: Advisor/Consultant (Terminated, November 30, 2023); MSD: Advisor/Consultant (Terminated, December 31, 2022), Honoraria (Terminated, December 31, 2022); Pfizer, Inc.: Advisor/Consultant (Terminated, November 30, 2023); Shionogi: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing)

Ahmed Babiker, MBBS: Beckman Coulter Inc.: Advisor/Consultant

Fatma Ben Abid, MD: No financial relationships to disclose

Frank P. Tverdek, PharmD: No financial relationships to disclose

Robert A. Bonomo, MD: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

recognize clinical challenges of dificult-to-treat gram-negative infection;
identify genotypes that underlie resistant phenotypes;
describe the characteristics and roles of new agents;
propose treatment strategies for dificult-to-treat gram-negative infection.